Breaking Finance News

Zacks Investment Research downgraded Trillium Therapeutics Inc. (NASDAQ:TRIL) to Hold in a report released today.

Zacks Investment Research has downgraded Trillium Therapeutics Inc.(NASDAQ:TRIL) to Hold in a report released on Friday September 16 2016.

On Wednesday August 17 2016, Zacks Investment Research reported on Trillium Therapeutics Inc.(NASDAQ:TRIL) raised the target price from $0.00 to $13.00. At the time, this indicated a possible downside of -0.09%.

Yesterday Trillium Therapeutics Inc. (NASDAQ:TRIL) traded 0.15% higher at $13.19. Trillium Therapeutics Inc.’s 50-day moving average is $11.93 and its two hundred day average is $10.20. With the last stock price close up 29.33% from the two hundred day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. Trading volume was was down over the average, with 28,322 shares of TRIL changing hands under the typical 68,945 shares..

Performance Chart:

Trillium Therapeutics Inc. (NASDAQ:TRIL)

With a total market value of $0.0, Trillium Therapeutics Inc. has a one-year low of $6.62 and a 52 week high of $19.08 with a PE ratio of 0.

More About Trillium Therapeutics Inc. (NASDAQ:TRIL)

Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is SIRPaFc, an antibody-like fusion protein, which is in Phase I clinical trial that blocks the activity of CD47 to promote the macrophage-mediated killing of tumor cells in a range of cancers. It also develops CD200 monoclonal antibody that blocks the activity of CD200 to evade attack from the immune system. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, and Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *